Navigation Links
The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
Date:12/3/2008

Despite roller-coaster changes in the U.S. and worldwide stock markets, the trend in health care employment could be counted on once again: tens of thousands of new jobs created in October, bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the numbers for October 2008 and announces the findings.

Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy experienced some subtle and – some might say – counterintuitive shifts in October, with the stock market moving like a roller coaster and gas prices dropping to sub-$2.00 per-gallon prices. According to MedZilla.com, the leading employment and career website for biotech, pharmaceuticals, health care, science and medical device, it found that one thing unchanged is the trend in health care job creation; 26,000 new jobs were created in October, putting health care employment growth at over 348,000 for the past twelve months.

News was not all good, however; as in previous months, some health care jobs were cut. In October, the most notable shrinkage was in Minnesota and the Northeast, but even the health system that announced the largest number of employment cutbacks – Alina in Minneapolis – was not planning to actively terminate employees. Instead, according to the St. Paul Pioneer Press, they will be eliminating positions via attrition – that is, not filling openings once current employees choose to depart. The greater number of outplacements, as in previous months, looks to come from pharmaceuticals. Once again, GlaxoSmithKline announced that they would be eliminating as many as 850 research and development positions. Most pharmaceutical companies that said they had planned to lay off employees did so under cover of restructuring efforts, as they – like most if not all companies in the country – work to eliminate costs and increase productivity at the same time.
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health
2. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
3. New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ
4. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
5. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
6. Mylan to Host Investor Day on October 3, 2007
7. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
9. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
10. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
11. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
(Date:12/2/2009)..., LIBREVILLE, Gabon, December 2 /PRNewswire/ -... Everyone,s Problem and Heritage" , Coinc... 2-3 June 2010 the,Gabonese Republic is hosting an... the issue of safeguarding biological resources in...ment and state leaders, ministers,scientific expe...
(Date:12/2/2009)... , CAMBRIDGE, Mass., Dec. 2 Te...aders in technology development and product integr...nounced the December 11th deadline for technology ... its 14th year, TechConnect World, in association ...TI), and the Clean Technology and Sustainable Indu...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte...el oral JAK2 inhibitor, SB1518, at The American So...tion in New Orleans. ,, Data will be presented ...lation trial of SB1518 detailing its safety, toler...) profile in dose levels ranging from 100 to 600 m...
(Date:12/2/2009)..., NANJING, China, Dec. 2 /PRNewswire-Asia/ -...Company") (NYSE: SCR ), a leading pharmaceutical...uring, and marketing of branded,generic and propri...at 105 of,its drugs have been included in China,s ...as issued by China,s Ministry of Human Resources a...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., R.I., May 28 Neurotech Pharmaceuticals, Inc. to..., NT-501, demonstrated a strong biologic effect ...ntosa (RP). RP is a slowly developing condition ...mp; cone photoreceptor cells in the retina that ov... eventually leads to blindness. RP is an orphan-de...
...NS, France, May 28 Poxel is a research integrated...ck Serono a division of,Merck KGaA, Germany, follo...est in diabetes research and development. It aims ...iseases (with a primary focus on Type 2,diabetes) ..., before,out-licensing these projects to major pha...
...rovides way of integrating and sustaining positive...28 In today,s uncertain times, increased stress c...rging wellness, growth and behavioral change parad...make healthier lifestyle choices and enjoy increas...llenges. , , The approach, called Reorganizationa...
Other Biology Technology:Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management 2Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress 2
(Date:12/3/2009)...ies can be likened to emptying a museum of its col...dicines into the trash, or replacing every local c...e of species and their habitats may not just make ... also put you at greater risk for catching some na...sity loss,"driven by the replacement of local spec...
(Date:12/3/2009)... CTRC-AACR San Antonio Breast Cancer Symposium con...e and world leaders from industry and academia wit... year, more than 8,500 scientists and other profes...ntion Center in San Antonio from Dec. 9-13, 2009. ...n Association for Cancer Research, the University ...
(Date:12/3/2009)...ty change in warmer water, according to an intrigu...ake some species more aggressive. , Experiments ...s Great Barrier Reef have shown for the first time..., or consistently bold, and that these individual ...ures rise. , A slight lift of just one or two de...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Fish with attitude: Some like it hot 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Growth Attracts Additional Investors to Sittercity com 55841 1Growth Attracts Additional Investors to Sittercity com 55841 2iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 1iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 2
...tin has received a six-year contract from the U.S....rt for the AN/UYQ-70 (Q-70) Advanced Display Syste... support at over $13 million a year for the first ...r the next four years, bringing the total potentia...t follows a recently awarded $525.6 million modifi...
...s March 19 during 12 p.m. Advertising Research Fou...e Research (R), a revolutionary media research fir... Advertising Research Foundation (ARF) conference ...identified key themes and styles that comprise imp...which were captured and delivered during the ARF,s...
...niversity of Florida have introduced ,Delicious, a...early, produces high yields, and is disease-resist...d texture with an edible skin, making it well-suit...or wine production. The name ,Delicious, was selec... sampled the fruit., According to Dr. Dennis J. Gr...
Other Biology News:U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
Mouse Anti-Human QPRT Monoclonal Antibody, Unconjugated, Clone 5D11 from ABR-Affinity BioReagents
ZOOM IPGRunner Mini-cell from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Agarose, Type C from Calbiochem
Biology Products: